Common narcolepsy symptoms such as excessive daytime sleepiness and sleep paralysis can affect how well you function during ...

Oveporexton significantly improves wakefulness and reduces cataplexy frequency in patients with narcolepsy type 1, according ...

For nearly 25 years, scientists believed they knew what caused the most severe form of narcolepsy. A new UCLA Health study ...

For nearly 25 years, scientists believed they knew what caused the most severe form of narcolepsy. A new UCLA Health study ...

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of ...

Pitolisant is now the only treatment option not scheduled as a controlled substance that is indicated for both excessive daytime sleepiness and cataplexy in pediatric and adult patients. The Food and ...

There is no biological measure for wakefulness. In a narcolepsy clinical trial, a patient lies down in a dark lab while clinicians count the minutes until sleep comes. The average time in four tests ...

Excessive daytime sleepiness was assessed using the Pediatric Daytime Sleepiness Scale total score. The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ...